Jane Street
IKT icon

Jane Street’s Inhibikase Therapeutics IKT Stock Holding History

Jane Street’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-116,003
Closed -$238K – 12224
2025
Q4 		$238K Buy
+116,003
New +$185K ﹤0.01% 9351
2025
Q2 		– Sell
-116,249
Closed -$255K – 10200
2025
Q1 		$255K Buy
+116,249
New +$292K ﹤0.01% 8080

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's IKT Position: Q1 2026 in Review

Jane Street sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 116,003 shares — an estimated $238K sold.

Jane Street first reported a position in IKT in Q1 2025 and held it in 2 quarters. The position peaked at $255K in Q1 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Jane Street reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 116,003 Inhibikase Therapeutics shares in Q1 2026, an estimated $238K.
  • Jane Street first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 2 quarters.
  • Jane Street's Inhibikase Therapeutics position peaked at $255K in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.